Clinical Trials Logo

Filter by:
NCT ID: NCT05076617 Enrolling by invitation - Clinical trials for Stereotypical Prolonged Seizures

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Start date: February 3, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

NCT ID: NCT05044221 Enrolling by invitation - Clinical trials for Intensive Care Unit Syndrome

Supporting the Recovery Needs of Patients Following Intensive Care

Start date: August 31, 2021
Phase:
Study type: Observational

Recovery for intensive care survivors is limited by ongoing problems with walking, strength, fatigue, mental distress and cognitive morbidity known as 'Post Intensive Care Syndrome'. There has been increasing interest in ways that clinicians can support patients in their post ICU recovery. The investigators are undertaking a co design approach to informing the design of a recovery pathway for patients who have been admitted to the intensive care to support them in their return to home, family and working responsibilities.

NCT ID: NCT05041309 Enrolling by invitation - Clinical trials for Solid and Hematological Malignancies

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Start date: December 15, 2021
Phase: Phase 2
Study type: Interventional

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.

NCT ID: NCT05039866 Enrolling by invitation - Fabry Disease Clinical Trials

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Start date: August 16, 2021
Phase:
Study type: Observational

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

NCT ID: NCT05016661 Enrolling by invitation - Migraine Clinical Trials

Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll approximately 666 patients across approximately 65 sites in the United States, Canada and Australia from the Phase 2 trial. Study subjects will be divided evenly across a low dose group and a high dose group. All patients will receive four treatment cycles of ABP-450 utilizing the Company's novel injection paradigm.

NCT ID: NCT04976946 Enrolling by invitation - Clinical trials for Complications; Urogenital, Postprocedural

Protocol for CAMUS Delphi Study

Start date: August 12, 2021
Phase:
Study type: Observational [Patient Registry]

Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.

NCT ID: NCT04911400 Enrolling by invitation - Clinical trials for Class III Malocclusion

Effects of Class III Elastics on Stability of Orthopaedic Class III Correction

Start date: July 22, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects of adding elastics to orthodontic retainers on the stability of class III correction and whether it reduces the need for jaw surgery.

NCT ID: NCT04905693 Enrolling by invitation - Clinical trials for Idiopathic Pulmonary Fibrosis

Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

TETON-OLE
Start date: September 6, 2022
Phase: Phase 3
Study type: Interventional

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.

NCT ID: NCT04886063 Enrolling by invitation - Alzheimer Disease Clinical Trials

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Start date: June 30, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.

NCT ID: NCT04760769 Enrolling by invitation - Parkinson Disease Clinical Trials

Open-label Trial in Parkinson's Disease (PD)

TEMPO-4
Start date: February 24, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.